Key clinical point: Tafamidis is the first disease-modifying medication for an underdiagnosed and surprisingly common form of cardiomyopathy.
Major finding: At 51 months of follow-up, patients on tafamidis at 80 mg/day were 43% less likely than those on 20 mg/day to have died, had a heart transplant, or ventricular assist device implantation.
Study details: This was a 21-month extension of the 30-month-long, phase 3 ATTR-ACT trial in which 441 patients with transthyretin amyloidosis cardiomyopathy (TAC) in 13 countries were randomized to tafamidis at either 80 mg or 20 mg per day or placebo.
Disclosures: The presenter reported receiving institutional research grant support from Pfizer, the study sponsor, and serving on a scientific advisory board for the company.
Damy T. ESC Heart Failure 2020.